^
    1d
    Adenosine A2B Receptor Promotes Tumor Progression and Metastases in Undifferentiated Pleomorphic Sarcoma. (PubMed, Clin Cancer Res)
    This study identifies ADORA2B as a critical regulator of metastatic progression in UPS, implicating it as a promising therapeutic target. Ongoing clinical trials targeting adenosine pathways further support the translational potential of ADORA2B inhibition to disrupt metastasis and improve outcomes for UPS patients.
    Journal
    |
    ADORA2B (Adenosine A2b Receptor)
    2d
    Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=98, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    2d
    Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards. (PubMed, J Transl Med)
    This study demonstrates the feasibility and clinical utility of integrating genomic-driven precision oncology with PDOX-based functional testing for MPNSTs. This strategy may support molecular tumor boards (MTBs) in their treatment decisions. The observed genomic stability supports the use of longitudinal tumor profiling to guide treatment, and the success of MEKi+BETi highlights its potential as a combination therapy for MPNSTs.
    Journal
    |
    NF1 (Neurofibromin 1)
    2d
    SarcAblate: HIFU Ablation of Soft Tissue Sarcoma (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Oxford University Hospitals NHS Trust | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    3d
    SB101: Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Sonnet BioTherapeutics | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    SON-1010
    4d
    68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    4d
    Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2023 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)
    4d
    Mammary malignant peripheral nerve sheath tumor in a 93-year-old male: case report. (PubMed, J Surg Case Rep)
    The patient underwent a right mastectomy, achieving a surgical clearance. After 3 months, he passed away with malignant pleural effusion due to lung metastasis.
    Journal
    |
    VIM (Vimentin) • TP63 (Tumor protein 63)
    6d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    6d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    6d
    Clinical study on the treatment of relapsed/refractory soft tissue sarcoma with liposome irinotecan combined with temozolomide and bevacizumab (ChiCTR2600117731)
    P=N/A, N=24, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Avastin (bevacizumab) • temozolomide
    6d
    A Case Report on the Use of a Lumbar Artery Perforator Flap to Repair Postoperative Defects in Refractory Dermatofibrosarcoma Protuberans (ChiCTR2600116571)
    P=N/A, N=1, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial